Description

Intestinal epithelium-specific growth factor that has been shown to reduce the severity of inflammatory disorders of the intestine in rodent models. Currently GLP-2 is used as a potential therapeutic agent for the human subjects with a broad variety of intestinal diseases characterized by intestinal damage and insufficiency.

SEQUENCE: H-His-Ala-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp-Arg-OH (trifluoroacetate salt)

ONE-LETTER SEQUENCE: HADGSFSDEMNTILDNLAARDFINWLIQTKITDR

MOLECULAR FORMULA: C₁₇₁H₂₆₆N₄₈O₅₆S₁

MOLECULAR WEIGHT: 3922.4

STORAGE CONDITIONS: -20 ± 5 °C

CAS REGISTRY NUMBER: [99120-49-7]

SYNONYMS:

RESEARCH AREA: Diabetes

REFERENCES:
D.J. Drucker, Trends Endocrinol. Metab., 10, 153 (1999)
D.J. Drucker et al., J. Parenter. Enteral Nutr., 23, 598 (1999)

SKU(s): GLUC-011A, GLUC-011B

KEYWORDS: hormone